<h3>关键见解</h3>
<ul>
<li>Inhibikase Therapeutics 的重要个人投资者持股表明，关键决策受到更大公众股东的影响</li>
<li>51% 的股份由前 11 大股东持有</li>
<li>Inhibikase Therapeutics 的机构持股比例为 30%</li>
</ul>
<p>特朗普承诺要 &#34;释放&#34; 美国的石油和天然气，这 15 只美国股票的发展有望受益。</p>
<p>每位 Inhibikase Therapeutics, Inc. (NASDAQ:IKT) 的投资者都应该了解最强大的股东群体。个人投资者持有 39% 的股份，是公司最大股东。换句话说，该群体在投资公司时将获得最多（或失去最多）的收益。</p>
<p>虽然个人投资者是上周 11% 价格上涨后获得最大收益的群体，但机构也获得了 30% 的收益。</p>
<p>在下面的图表中，我们聚焦于 Inhibikase Therapeutics 的不同持股群体。</p>
<p>查看我们对 Inhibikase Therapeutics 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/113910012-ownership-breakdown-1-dark-2/1765881740832?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1642" height="732" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/113910012-ownership-breakdown-1-dark-2/1765881740832"/></p>
<p>NasdaqCM:IKT 持股分布 2025 年 12 月 16 日</p>
<h2>机构持股对 Inhibikase Therapeutics 的启示是什么？</h2>
<p>许多机构将其业绩与接近当地市场的指数进行比较。因此，他们通常更关注纳入主要指数的公司。</p>
<p>我们可以看到 Inhibikase Therapeutics 确实有机构投资者，他们持有公司相当一部分的股票。这表明在专业投资者中有一定的可信度。但我们不能仅仅依赖这一事实，因为机构有时也会做出糟糕的投资，就像其他人一样。当多个机构持有一只股票时，总是存在他们处于 “拥挤交易” 的风险。当这种交易出现问题时，多个参与方可能会争相快速出售股票。在没有增长历史的公司中，这种风险更高。您可以在下面看到 Inhibikase Therapeutics 的历史收益和收入，但请记住，事情总是有更多的背景。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/113910012-earnings-and-revenue-growth-1-dark-2/1765881742801?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1642" height="1048" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/113910012-earnings-and-revenue-growth-1-dark-2/1765881742801"/></p>
<p>NasdaqCM:IKT 收益和收入增长 2025 年 12 月 16 日</p>
<p>看起来对冲基金持有 Inhibikase Therapeutics 11% 的股份。这很有趣，因为对冲基金可能非常活跃并且具有激进性。许多基金寻找中期催化剂，以推动股价上涨。Sands Capital Ventures, LLC 目前是最大股东，持有 11% 的流通股。相比之下，第二和第三大股东分别持有约 5.4% 和 5.2% 的股份。</p>
<p>查看股东登记，我们可以看到前 11 大股东控制了 51% 的股份，这意味着没有单一股东拥有多数股权。</p>
<p>研究机构持股是评估和筛选股票预期表现的好方法。通过研究分析师的情绪也可以实现同样的目的。覆盖该股票的分析师很多，因此查看他们的预测也许值得。</p>
<h2>Inhibikase Therapeutics 的内部持股</h2>
<p>内部人的定义在不同国家之间可能略有不同，但董事会成员始终算在内。管理层最终对董事会负责。然而，管理者作为执行董事会成员并不罕见，特别是如果他们是创始人或首席执行官。</p>
<p>内部持股是积极的，当它表明领导层像公司的真正所有者一样思考时。然而，高内部持股也可能赋予公司内部小团体巨大的权力。在某些情况下，这可能是负面的。</p>
<p>我们最新的数据表明，内部人持有一些 Inhibikase Therapeutics, Inc. 的股份。作为个人，内部人共同持有价值 790 万美元的公司股份，公司的市值为 1.9 亿美元。看到内部人有一些投资是好的，但我们通常希望看到更高的内部持股。检查这些内部人是否在增持可能值得关注。</p>
<h2>公众持股</h2>
<p>公众——包括散户投资者——持有公司 39% 的股份，因此不能轻易被忽视。尽管这一持股规模相当可观，但如果决策与其他大股东不同，可能不足以改变公司政策。</p>
<h2>私募股权持股</h2>
<p>私募股权公司持有 11% 的股份，能够在以价值创造为重点的公司战略中发挥作用。有时我们看到私募股权公司长期持有，但一般来说，他们的投资周期较短，并且——顾名思义——不太会投资于上市公司。经过一段时间，他们可能会考虑出售并将资本重新部署到其他地方。</p>
<h2>私人公司持股</h2>
<p>我们的数据表明，私人公司持有公司 5.0% 的股份。深入研究这一点可能值得。如果相关方，例如内部人，对这些私人公司之一有兴趣，则应在年度报告中披露。私人公司也可能对公司有战略利益。</p>
<h2>下一步：</h2>
<p>考虑拥有公司股份的不同群体总是值得的。但要更好地理解 Inhibikase Therapeutics，我们需要考虑许多其他因素。例如，我们已经确定了 <strong>Inhibikase Therapeutics 的 4 个警示信号</strong>（其中 3 个可能是严重的），您应该注意。</p>
<p>但最终 <strong>未来</strong> 而不是过去，将决定这家公司的所有者将如何表现。因此，我们认为查看这份免费的报告，了解分析师是否预测更光明的未来是明智的。</p>
<p>注意：本文中的数据是使用过去十二个月的数据计算的，指的是财务报表日期所在月份的最后一天结束的 12 个月期间。这可能与全年年度报告数据不一致。</p>
<p>国防和灾难的移动基础设施</p>
<p>下一波机器人技术不是人形机器人，而是能够在 30 分钟内在任何地方提供 5G、ISR 和雷达的完全自主塔。</p>
<p>在下一轮合同之前获取投资者简报</p>
<p>代表 CiTech 赞助</p>

<p>Inhibikase Therapeutics（纳斯达克代码：IKT）上周股价上涨了 11%，最受益的是持有 39% 股份的散户投资者。机构持有 30% 的股份，而对冲基金和私募股权公司各持有 11%。前 11 大股东控制着公司 51% 的股份。内部持股价值为 790 万美元。公众的持股比例虽然可观，但单独不足以影响公司的政策</p>

<h3>Key Insights</h3>
<div class="lb-trans"><h3>关键见解</h3>
</div><ul>
<li>Inhibikase Therapeutics' significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public</li>
<li>51% of the business is held by the top 11 shareholders</li>
<li>Institutional ownership in Inhibikase Therapeutics is 30%</li>
</ul>
<div class="lb-trans"><ul>
<li>Inhibikase Therapeutics 的重要个人投资者持股表明，关键决策受到更大公众股东的影响</li>
<li>51% 的股份由前 11 大股东持有</li>
<li>Inhibikase Therapeutics 的机构持股比例为 30%</li>
</ul>
</div><p>Trump has pledged to &#34;unleash&#34; American oil and gas and these 15 US stocks have developments that are poised to benefit.</p>
<div class="lb-trans"><p>特朗普承诺要 &#34;释放&#34; 美国的石油和天然气，这 15 只美国股票的发展有望受益。</p>
</div><p>Every investor in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) should be aware of the most powerful shareholder groups. With 39% stake, individual investors possess the maximum shares in the company. In other words, the group stands to gain the most (or lose the most) from their investment into the company.</p>
<div class="lb-trans"><p>每位 Inhibikase Therapeutics, Inc. (NASDAQ:IKT) 的投资者都应该了解最强大的股东群体。个人投资者持有 39% 的股份，是公司最大股东。换句话说，该群体在投资公司时将获得最多（或失去最多）的收益。</p>
</div><p>While individual investors were the group that reaped the most benefits after last week’s 11% price gain, institutions also received a 30% cut.</p>
<div class="lb-trans"><p>虽然个人投资者是上周 11% 价格上涨后获得最大收益的群体，但机构也获得了 30% 的收益。</p>
</div><p>In the chart below, we zoom in on the different ownership groups of Inhibikase Therapeutics.</p>
<div class="lb-trans"><p>在下面的图表中，我们聚焦于 Inhibikase Therapeutics 的不同持股群体。</p>
</div><p>Check out our latest analysis for Inhibikase Therapeutics</p>
<div class="lb-trans"><p>查看我们对 Inhibikase Therapeutics 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/113910012-ownership-breakdown-1-dark-2/1765881740832" alt="" original-src="https://images.simplywall.st/asset/chart/113910012-ownership-breakdown-1-dark-2/1765881740832"/></p>
<p>NasdaqCM:IKT Ownership Breakdown December 16th 2025</p>
<div class="lb-trans"><p>NasdaqCM:IKT 持股分布 2025 年 12 月 16 日</p>
</div><h2>What Does The Institutional Ownership Tell Us About Inhibikase Therapeutics?</h2>
<div class="lb-trans"><h2>机构持股对 Inhibikase Therapeutics 的启示是什么？</h2>
</div><p>Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.</p>
<div class="lb-trans"><p>许多机构将其业绩与接近当地市场的指数进行比较。因此，他们通常更关注纳入主要指数的公司。</p>
</div><p>We can see that Inhibikase Therapeutics does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Inhibikase Therapeutics' historic earnings and revenue below, but keep in mind there's always more to the story.</p>
<div class="lb-trans"><p>我们可以看到 Inhibikase Therapeutics 确实有机构投资者，他们持有公司相当一部分的股票。这表明在专业投资者中有一定的可信度。但我们不能仅仅依赖这一事实，因为机构有时也会做出糟糕的投资，就像其他人一样。当多个机构持有一只股票时，总是存在他们处于 “拥挤交易” 的风险。当这种交易出现问题时，多个参与方可能会争相快速出售股票。在没有增长历史的公司中，这种风险更高。您可以在下面看到 Inhibikase Therapeutics 的历史收益和收入，但请记住，事情总是有更多的背景。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/113910012-earnings-and-revenue-growth-1-dark-2/1765881742801" alt="" original-src="https://images.simplywall.st/asset/chart/113910012-earnings-and-revenue-growth-1-dark-2/1765881742801"/></p>
<p>NasdaqCM:IKT Earnings and Revenue Growth December 16th 2025</p>
<div class="lb-trans"><p>NasdaqCM:IKT 收益和收入增长 2025 年 12 月 16 日</p>
</div><p>It looks like hedge funds own 11% of Inhibikase Therapeutics shares. That's interesting, because hedge funds can be quite active and activist. Many look for medium term catalysts that will drive the share price higher. Sands Capital Ventures, LLC is currently the largest shareholder, with 11% of shares outstanding. In comparison, the second and third largest shareholders hold about 5.4% and 5.2% of the stock.</p>
<div class="lb-trans"><p>看起来对冲基金持有 Inhibikase Therapeutics 11% 的股份。这很有趣，因为对冲基金可能非常活跃并且具有激进性。许多基金寻找中期催化剂，以推动股价上涨。Sands Capital Ventures, LLC 目前是最大股东，持有 11% 的流通股。相比之下，第二和第三大股东分别持有约 5.4% 和 5.2% 的股份。</p>
</div><p>Looking at the shareholder registry, we can see that 51% of the ownership is controlled by the top 11 shareholders, meaning that no single shareholder has a majority interest in the ownership.</p>
<div class="lb-trans"><p>查看股东登记，我们可以看到前 11 大股东控制了 51% 的股份，这意味着没有单一股东拥有多数股权。</p>
</div><p>Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.</p>
<div class="lb-trans"><p>研究机构持股是评估和筛选股票预期表现的好方法。通过研究分析师的情绪也可以实现同样的目的。覆盖该股票的分析师很多，因此查看他们的预测也许值得。</p>
</div><h2>Insider Ownership Of Inhibikase Therapeutics</h2>
<div class="lb-trans"><h2>Inhibikase Therapeutics 的内部持股</h2>
</div><p>The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.</p>
<div class="lb-trans"><p>内部人的定义在不同国家之间可能略有不同，但董事会成员始终算在内。管理层最终对董事会负责。然而，管理者作为执行董事会成员并不罕见，特别是如果他们是创始人或首席执行官。</p>
</div><p>Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.</p>
<div class="lb-trans"><p>内部持股是积极的，当它表明领导层像公司的真正所有者一样思考时。然而，高内部持股也可能赋予公司内部小团体巨大的权力。在某些情况下，这可能是负面的。</p>
</div><p>Our most recent data indicates that insiders own some shares in Inhibikase Therapeutics, Inc.. As individuals, the insiders collectively own US$7.9m worth of the US$190m company. It is good to see some investment by insiders, but we usually like to see higher insider holdings. It might be worth checking if those insiders have been buying.</p>
<div class="lb-trans"><p>我们最新的数据表明，内部人持有一些 Inhibikase Therapeutics, Inc. 的股份。作为个人，内部人共同持有价值 790 万美元的公司股份，公司的市值为 1.9 亿美元。看到内部人有一些投资是好的，但我们通常希望看到更高的内部持股。检查这些内部人是否在增持可能值得关注。</p>
</div><h2>General Public Ownership</h2>
<div class="lb-trans"><h2>公众持股</h2>
</div><p>The general public-- including retail investors -- own 39% stake in the company, and hence can't easily be ignored. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.</p>
<div class="lb-trans"><p>公众——包括散户投资者——持有公司 39% 的股份，因此不能轻易被忽视。尽管这一持股规模相当可观，但如果决策与其他大股东不同，可能不足以改变公司政策。</p>
</div><h2>Private Equity Ownership</h2>
<div class="lb-trans"><h2>私募股权持股</h2>
</div><p>With an ownership of 11%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Sometimes we see private equity stick around for the long term, but generally speaking they have a shorter investment horizon and -- as the name suggests -- don't invest in public companies much. After some time they may look to sell and redeploy capital elsewhere.</p>
<div class="lb-trans"><p>私募股权公司持有 11% 的股份，能够在以价值创造为重点的公司战略中发挥作用。有时我们看到私募股权公司长期持有，但一般来说，他们的投资周期较短，并且——顾名思义——不太会投资于上市公司。经过一段时间，他们可能会考虑出售并将资本重新部署到其他地方。</p>
</div><h2>Private Company Ownership</h2>
<div class="lb-trans"><h2>私人公司持股</h2>
</div><p>Our data indicates that Private Companies hold 5.0%, of the company's shares. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.</p>
<div class="lb-trans"><p>我们的数据表明，私人公司持有公司 5.0% 的股份。深入研究这一点可能值得。如果相关方，例如内部人，对这些私人公司之一有兴趣，则应在年度报告中披露。私人公司也可能对公司有战略利益。</p>
</div><h2>Next Steps:</h2>
<div class="lb-trans"><h2>下一步：</h2>
</div><p>It's always worth thinking about the different groups who own shares in a company. But to understand Inhibikase Therapeutics better, we need to consider many other factors. For instance, we've identified <strong>4 warning signs for Inhibikase Therapeutics</strong> (3 are potentially serious) that you should be aware of.</p>
<div class="lb-trans"><p>考虑拥有公司股份的不同群体总是值得的。但要更好地理解 Inhibikase Therapeutics，我们需要考虑许多其他因素。例如，我们已经确定了 <strong>Inhibikase Therapeutics 的 4 个警示信号</strong>（其中 3 个可能是严重的），您应该注意。</p>
</div><p>But ultimately <strong>it is the future</strong>, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.</p>
<div class="lb-trans"><p>但最终 <strong>未来</strong> 而不是过去，将决定这家公司的所有者将如何表现。因此，我们认为查看这份免费的报告，了解分析师是否预测更光明的未来是明智的。</p>
</div><p>NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.</p>
<div class="lb-trans"><p>注意：本文中的数据是使用过去十二个月的数据计算的，指的是财务报表日期所在月份的最后一天结束的 12 个月期间。这可能与全年年度报告数据不一致。</p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>国防和灾难的移动基础设施</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波机器人技术不是人形机器人，而是能够在 30 分钟内在任何地方提供 5G、ISR 和雷达的完全自主塔。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一轮合同之前获取投资者简报</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>代表 CiTech 赞助</p>
</div>

While institutions invested in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) benefited from last week's 11% gain, individual investors stood to gain the most

尽管机构投资者在 Inhibikase Therapeutics, Inc.（NASDAQ:IKT）中投资并从上周 11% 的涨幅中获益，但个人投资者才是最大的受益者